HSCT pairs, disease, and transplantation characteristics
| Characteristics . | Values . |
|---|---|
| Recipients (n = 211) | |
| Median age, y | 32.5 |
| Male, n (%) | 117 (56) |
| Children, 15 y or younger, n (%) | 41 (19) |
| Positive CMV serology, n (%) | 131 (62) |
| MICA-129 polymorphism | |
| Genotype frequencies | |
| Met/met, n (%) | 15 (7) |
| Met/val, n (%) | 99 (47) |
| Val/val, n (%) | 97 (46) |
| Allele frequencies | |
| Met, n (%) | 113 (27) |
| Val, n (%) | 309 (73) |
| Underlying diagnosis | |
| Chronic leukemia, n (%) | 36 (17) |
| Acute leukemia, n (%) | 98 (46) |
| Other malignant disorders, n (%) | 52 (25) |
| Nonmalignant disorder | 25 (12) |
| Disease status for malignant disorders | |
| Early, n (%) | 126 (68) |
| Intermediate, n (%) | 35 (19) |
| Advanced, n (%) | 22 (12) |
| Unknown, n (%) | 3 (1) |
| Donors | |
| Median age, y | 32.4 |
| Male, n (%) | 109 (52) |
| Female donor to male recipient, n (%) | 55 (26) |
| ABO major incompatibility, n (%) | 30 (14) |
| Positive CMV serology, n (%) | 108 (51) |
| MICA-129 polymorphism | |
| Genotype frequencies | |
| Met/met, n (%) | 15 (7) |
| Met/val, n (%) | 99 (47) |
| Val/val, n (%) | 97 (46) |
| Allele frequencies | |
| Met, n (%) | 113 (27) |
| Val, n (%) | 309 (73) |
| Transplantation | |
| Source of stem cells | |
| BM, n (%) | 146 (69) |
| PB, n (%) | 65 (31) |
| Nonmyeloablation | 20 (9) |
| GVHD prophylaxis | |
| CSA, n (%) | 6 (3) |
| CSA + MTX, n (%) | 175 (83) |
| CSA ± others, n (%) | 23 (11) |
| Unknown, n (%) | 7 (3) |
| Conditioning | |
| TBI-based, n (%) | 87 (41) |
| Bu-based, n (%) | 124 (59) |
| Characteristics . | Values . |
|---|---|
| Recipients (n = 211) | |
| Median age, y | 32.5 |
| Male, n (%) | 117 (56) |
| Children, 15 y or younger, n (%) | 41 (19) |
| Positive CMV serology, n (%) | 131 (62) |
| MICA-129 polymorphism | |
| Genotype frequencies | |
| Met/met, n (%) | 15 (7) |
| Met/val, n (%) | 99 (47) |
| Val/val, n (%) | 97 (46) |
| Allele frequencies | |
| Met, n (%) | 113 (27) |
| Val, n (%) | 309 (73) |
| Underlying diagnosis | |
| Chronic leukemia, n (%) | 36 (17) |
| Acute leukemia, n (%) | 98 (46) |
| Other malignant disorders, n (%) | 52 (25) |
| Nonmalignant disorder | 25 (12) |
| Disease status for malignant disorders | |
| Early, n (%) | 126 (68) |
| Intermediate, n (%) | 35 (19) |
| Advanced, n (%) | 22 (12) |
| Unknown, n (%) | 3 (1) |
| Donors | |
| Median age, y | 32.4 |
| Male, n (%) | 109 (52) |
| Female donor to male recipient, n (%) | 55 (26) |
| ABO major incompatibility, n (%) | 30 (14) |
| Positive CMV serology, n (%) | 108 (51) |
| MICA-129 polymorphism | |
| Genotype frequencies | |
| Met/met, n (%) | 15 (7) |
| Met/val, n (%) | 99 (47) |
| Val/val, n (%) | 97 (46) |
| Allele frequencies | |
| Met, n (%) | 113 (27) |
| Val, n (%) | 309 (73) |
| Transplantation | |
| Source of stem cells | |
| BM, n (%) | 146 (69) |
| PB, n (%) | 65 (31) |
| Nonmyeloablation | 20 (9) |
| GVHD prophylaxis | |
| CSA, n (%) | 6 (3) |
| CSA + MTX, n (%) | 175 (83) |
| CSA ± others, n (%) | 23 (11) |
| Unknown, n (%) | 7 (3) |
| Conditioning | |
| TBI-based, n (%) | 87 (41) |
| Bu-based, n (%) | 124 (59) |
CMV indicates cytomegalovirus; PB, peripheral blood; CSA, cyclosporin A; MTX, methotrexate; TBI, total body irradiation; and Bu, busulfan.